Insights on the Mammalian Polyclonal IgG Antibody Global Market to 2027 – Rising Need for Antibodies for Multiple Immunoassay Tests Drives Growth – ResearchAndMarkets.com

Insights on the Mammalian Polyclonal IgG Antibody Global Market to 2027 – Rising Need for Antibodies for Multiple Immunoassay Tests Drives Growth – ResearchAndMarkets.com




Insights on the Mammalian Polyclonal IgG Antibody Global Market to 2027 – Rising Need for Antibodies for Multiple Immunoassay Tests Drives Growth – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Mammalian Polyclonal IgG Antibody Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” report has been added to ResearchAndMarkets.com’s offering.

The global mammalian polyclonal IgG antibody market size reached US$ 984.81 Million in 2021. Looking forward, the publisher expects the market to reach US$ 1,351.73 Million by 2027, exhibiting a CAGR of 5.42% during 2021-2027.

Mammalian polyclonal immunoglobulins (IgG) antibody refers to antigens or vaccinations that are manufactured through inoculation of various mammals, including mice, rabbits, and goats. During this procedure, an antigen is administered via injectable into the mammal body to activate the B-lymphocytes that supply IgG.

These antibodies are used in labeling reagents in multiple immunoassay tests, including enzyme-linked immunosorbent assay (ELISA), western blot tests, immunoradiometric assay (IRMA), and radioimmunoassay (RIA). Apart from this, the process does not require skilled professionals to produce large batches of vaccinations.

Mammalian polyclonal IgG antibody helps create multiple therapeutics, diagnose various ailments, and perform antibody identification and flow cytometry. As a result, they find extensive applications in biochemical research to detect denatured proteins and examine diseases and their treatments. At present, they are commercially available in cardiac, metabolic, and renal marker product variants.

The increasing prevalence of various chronic disorders, including cancer and autoimmune ailments, and the rising need for antibodies for multiple immunoassay tests and therapeutic and analytical applications in research settings are primarily driving the market growth.

In line with this, significant investments in biotechnology and pharmaceutical companies by governments to formulate effective novel vaccinations and injectables through advanced technologies are acting as another growth-inducing factor.

Additionally, the ongoing innovation of creative mammalian antibodies by biopharma organizations for quality control (QC) is contributing to the market growth.

Moreover, the escalating biomarkers approval and their extensive usage by clinicians for accurate and rapid diagnosis of B-cell lymphoma and leukemia are supporting the market growth. Apart from this, significant enhancements in the healthcare infrastructure and research and development (R&D) activities to enhance antibody efficacy are creating a positive outlook for the market.

Companies Mentioned

  • Abbiotec Inc.
  • Abcam plc
  • Bio-Rad Laboratories Inc.
  • Cell Signaling Technology Inc.
  • Creative Diagnostics
  • Elabscience Biotechnology Inc.
  • Geno Technology Inc.
  • Merck KGaA
  • Proteintech Group Inc.
  • STEMCELL Technologies Inc.
  • Thermo Fisher Scientific Inc.

Key Market Segmentation:

The publisher provides an analysis of the key trends in each sub-segment of the global mammalian polyclonal IgG antibody market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, product, application and end use.

Breakup by Type:

  • Goat
  • Rabbit
  • Horse
  • Mouse
  • Others

Breakup by Product:

  • Cardiac Markers
  • Metabolic Markers
  • Renal Markers
  • Others

Breakup by Application:

  • ELISA
  • Immunoturbidimetry
  • Immunoelectrophoresis
  • Antibody Identification
  • Immunohistochemistry
  • Immunocytochemistry
  • Western Blotting

Breakup by End Use:

  • Hospitals
  • Diagnostic Centers
  • Academic and Research Institutes

Breakup by Region:

North America

  • United States
  • Canada

Asia-Pacific

  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others

Europe

  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others

Latin America

  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Key Questions Answered in This Report:

  • How has the global mammalian polyclonal IgG antibody market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global mammalian polyclonal IgG antibody market?
  • What are the key regional markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the product?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the end use?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global mammalian polyclonal IgG antibody market and who are the key players?
  • What is the degree of competition in the industry?

For more information about this report visit https://www.researchandmarkets.com/r/24os02

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900